Health-related Quality of Life in Adults With Hemophilia B After Gene Therapy With Fidanacogene Elaparvovec in the BENEGENE-2 Trial

Sylvia von Mackensen, PhD
Highlights From the 17th Annual Congress of EAHAD

Health-related Quality of Life in Adults With Hemophilia B After Gene Therapy With Fidanacogene Elaparvovec in the BENEGENE-2 Trial

Presented by: Sylvia von Mackensen, PhD

S. von Mackensen1, C. N. Bagot2, A. Lienhart3, F. Sahin4, H. Tran5, J. Rupon6, A. Chhabra7, M. Kalac7, J. Fuiman6, J. McKay6, P. Sun9, F. Plonski6

  1. Department of Medical Psychology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany
  2. Department of Haematology, Glasgow Royal Infirmary, Glasgow, United Kingdom
  3. Hopital Cardiologique Louis Pradel – CRTH, Bron, France
  4. Ege University Medical Faculty Hospital, Izmir, Türkiye
  5. The Alfred Hospital, Melbourne, Australia
  6. Pfizer Inc, Collegeville, PA
  7. Pfizer Inc, New York, NY
  8. Pfizer Inc, Groton, CT
  9. Pfizer Inc, Cambridge, MA, United States

RELATED CONTENT

Image

Supported through educational grants from BioMarin, CSL Behring, Pfizer Inc., Roche, and Spark Therapeutics

Essential SSL